Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Compass Therapeutics, Inc.

Market Cap 369M 322M 297M 279M 522M 34.79B 525M 3.53B 1.37B 17.15B 1.39B 1.36B 59.43B P/E 2026 *
-4.68x
P/E 2027 * -4.41x
Enterprise Value 219M 191M 176M 166M 310M 20.66B 312M 2.09B 813M 10.18B 823M 805M 35.28B EV / Sales 2026 *
-98.9x
EV / Sales 2027 * 9.24x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.73%
1 week+0.50%
Current month-15.13%
1 month+10.38%
3 months-62.03%
6 months-59.92%
Current year-62.38%
1 week 1.96
Extreme 1.96
2.14
1 month 1.75
Extreme 1.7506
2.47
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 56 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Date Insider Type Main position Quantity % Market Cap.
04-28Buy

Controller/Auditor

15,000 0.0083%
04-28Buy

General Counsel

25,000 0.0139%
02-07Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%+0.50%-15.13%-39.88% 369M
-2.23%-0.03%+61.34%+109.10% 56.24B
+4.60%+5.85%+54.47%+43.04% 43.76B
-1.44%+1.51%-12.94%-17.33% 23.32B
-2.69%-0.95%-3.68%+374.02% 21.34B
+3.22%+3.77%+19.92%-35.05% 15.75B
-0.67%+1.18%+12.91%-39.22% 15.6B
-1.01%-2.97%+27.42%+174.08% 13.18B
+3.07%+3.59%+25.54% - 12.01B
+4.95%+7.51%+123.21%+249.05% 11.87B
Average +0.85%+4.06%+29.31%+90.87% 21.34B
Weighted average by Cap. +0.50%+3.55%+37.92%+97.65%

Financials

2026 *2027 *
Net sales -2.22M -1.93M -1.78M -1.67M -3.13M -209M -3.15M -21.17M -8.22M -103M -8.32M -8.14M -357M 25.67M 22.37M 20.62M 19.4M 36.29M 2.42B 36.54M 245M 95.28M 1.19B 96.37M 94.3M 4.13B
Net income -82.94M -72.27M -66.62M -62.66M -117M -7.82B -118M -793M -308M -3.85B -311M -305M -13.35B -89.85M -78.29M -72.17M -67.88M -127M -8.47B -128M -859M -333M -4.17B -337M -330M -14.46B
Net Debt -150M -131M -120M -113M -212M -14.14B -213M -1.43B -557M -6.97B -563M -551M -24.15B -132M -115M -106M -99.72M -187M -12.44B -188M -1.26B -490M -6.13B -495M -485M -21.25B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
18/06/26 2.020 $ -1.46% 9,237,880
17/06/26 2.050 $ +4.06% 3,744,497
16/06/26 1.970 $ -3.43% 2,532,656
15/06/26 2.040 $ +0.49% 2,174,768
12/06/26 2.030 $ +1.00% 2,049,688
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
2.050USD
Average target price
8.818USD
Spread / Average Target
+330.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!